Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash & Equivalents (2020 - 2025)

Journey Medical's Cash & Equivalents history spans 6 years, with the latest figure at $24.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 18.64% year-over-year to $24.1 million, compared with a TTM value of $24.1 million through Dec 2025, up 18.64%, and an annual FY2025 reading of $24.1 million, up 18.64% over the prior year.
  • Cash & Equivalents for Q4 2025 was $24.1 million at Journey Medical, down from $24.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $49.1 million in Q4 2021, with the low at $8.2 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $26.4 million, with a median of $24.1 million recorded in 2024.
  • Year-over-year, Cash & Equivalents soared 495.21% in 2021 and then tumbled 78.48% in 2023.
  • Tracing DERM's Cash & Equivalents over 5 years: stood at $49.1 million in 2021, then tumbled by 34.8% to $32.0 million in 2022, then dropped by 14.37% to $27.4 million in 2023, then dropped by 25.89% to $20.3 million in 2024, then increased by 18.64% to $24.1 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Cash & Equivalents are $24.1 million (Q4 2025), $24.9 million (Q3 2025), and $20.3 million (Q2 2025).